When fluid accumulates in the tiny air sacs of the lungs, oxygen cannot reach the bloodstream efficiently, leading to dangerously low oxygen levels throughout the body. Treatment focuses on supporting breathing, addressing the underlying cause, and preventing complications while the lungs heal.
The primary goal when treating acute respiratory distress syndrome is to maintain adequate oxygen levels in the blood so that vital organs can continue functioning properly. Because ARDS typically develops as a complication of another serious illness or injury, healthcare providers must address both the lung damage and the condition that triggered it. Treatment strategies depend heavily on how severe the syndrome is, which underlying problem caused it, and the overall health status of each individual patient.
ARDS affects approximately 200,000 people in the United States each year, and most patients require admission to an intensive care unit where specialized teams can monitor and support their breathing around the clock. The condition can worsen rapidly, sometimes within hours, making quick recognition and intervention essential for the best possible outcomes.
There is currently no cure that can reverse ARDS once it develops. Instead, medical treatment is supportive, meaning it helps the body manage symptoms and gives the lungs time to heal on their own. With proper care, an estimated 60% to 75% of people who develop ARDS survive the condition, though recovery can be lengthy and challenging.
ARDS is always a medical emergency. Most cases occur in people already hospitalized for another serious condition, but if someone who is not in a hospital develops severe shortness of breath, rapid breathing, or a bluish color to the lips or fingernails, they should go to the emergency department immediately or call emergency services. These symptoms indicate that the body is not getting enough oxygen, which can quickly become life-threatening.
The foundation of ARDS treatment is oxygen therapy. Because the damaged lungs cannot move enough oxygen into the bloodstream on their own, patients need supplemental oxygen delivered through various methods. The simplest approach involves delivering oxygen through tubes that rest in the nose or through a face mask. However, many patients with ARDS need more advanced breathing support.
Mechanical ventilation is often necessary when oxygen levels remain dangerously low despite supplemental oxygen. A ventilator is a machine that helps a person breathe by pushing air into the lungs through a tube placed in the windpipe. This procedure, while potentially uncomfortable, is often life-saving. Healthcare providers use a specific strategy called low tidal volume ventilation, which means the ventilator delivers smaller breaths than normal. This approach has been proven to improve survival in ARDS by reducing additional damage to already injured lungs. The ventilator settings are carefully adjusted to maintain adequate oxygen while minimizing harm, typically targeting a tidal volume of about 6 milliliters per kilogram of ideal body weight.
Another technique called positive end-expiratory pressure, or PEEP, is used with mechanical ventilation. PEEP keeps the airways from completely collapsing at the end of each breath out, which helps more of the lung stay open and functional. This allows better oxygen exchange without requiring dangerously high oxygen concentrations or excessive pressure that could further injure lung tissue.
Some patients may benefit from noninvasive ventilation methods before requiring full mechanical ventilation. Bilevel positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) machines deliver air pressure through a face mask rather than a tube in the windpipe. These devices help keep airways open and can improve oxygen levels in less severe cases, though they do not work for everyone with ARDS.
Fluid management is another crucial component of standard ARDS treatment. While patients need enough fluids to maintain blood pressure and organ function, too much fluid can worsen the accumulation of fluid in the lungs. Healthcare providers follow a conservative fluid strategy, carefully balancing the body’s fluid levels to avoid overload while ensuring adequate circulation to organs. This approach has been shown to improve outcomes and reduce the time patients spend on ventilators.
Prone positioning involves turning patients onto their stomachs rather than keeping them on their backs. This simple but labor-intensive technique can dramatically improve oxygen levels in severe ARDS. When lying face-down, different parts of the lungs expand more effectively, and fluid redistributes in ways that improve gas exchange. Studies have shown that prone positioning can improve survival in patients with severe ARDS. Patients typically spend 16 hours or more per day in the prone position, with careful monitoring to prevent pressure sores and other complications.
Identifying and treating the underlying cause of ARDS is essential for recovery. If a bacterial infection such as pneumonia or sepsis triggered the lung injury, appropriate antibiotics must be started quickly. If the cause was aspiration of stomach contents, preventing further aspiration is critical. When trauma or burns led to ARDS, managing those injuries becomes part of the overall treatment plan. Without addressing the root cause, the lungs cannot begin to heal even with optimal supportive care.
Pain management and sedation are often necessary, especially for patients on mechanical ventilators. Being intubated and connected to a breathing machine can be uncomfortable and anxiety-provoking. Medications help keep patients comfortable and calm, which also allows them to tolerate the ventilator better. However, medical teams now aim to use the minimum amount of sedation necessary, as excessive sedation can prolong recovery and increase complications.
Neuromuscular blocking agents are medications that temporarily paralyze muscles. In severe ARDS, these drugs may be used for short periods to help the ventilator work more effectively by preventing the patient from fighting against the machine. While this sounds frightening, patients receive sedation alongside these medications so they are not aware of being unable to move. The use of neuromuscular blockers must be carefully monitored and limited in duration to avoid prolonged muscle weakness.
Corticosteroids are anti-inflammatory medications that may be used in some cases of ARDS. The rationale is that ARDS involves significant lung inflammation, and corticosteroids might reduce this inflammatory response. However, the evidence for their effectiveness is mixed. Some studies suggest potential benefits, particularly when started early in the disease course, while others show no clear advantage. Doctors must weigh the potential benefits against risks such as increased infection susceptibility and delayed wound healing when considering corticosteroid treatment.
Inhaled pulmonary vasodilators such as nitric oxide may be tried in severe cases to improve oxygen levels. These medications work by relaxing blood vessels in the lungs, particularly in areas that are well-ventilated, which can improve the match between airflow and blood flow. While inhaled vasodilators can temporarily improve oxygenation, they have not been shown to reduce mortality or shorten time on the ventilator, so their use remains selective.
Nutritional support becomes important as ARDS treatment continues. Patients on ventilators cannot eat normally, so nutrition is provided through tubes placed in the stomach or through intravenous lines. Adequate nutrition supports the body’s healing processes and helps maintain strength, though the optimal timing and composition of nutritional support in ARDS continues to be studied.
Beyond standard treatments, researchers are investigating various innovative approaches to improve outcomes for people with ARDS. Clinical trials test new medications, devices, and strategies that might someday become part of routine care. These studies typically progress through phases, with Phase I trials focusing primarily on safety, Phase II trials examining whether a treatment shows promise of effectiveness, and Phase III trials comparing new treatments against current standard care in larger groups of patients.
One area of ongoing research involves alternative ventilation modes for patients who do not respond adequately to conventional mechanical ventilation. High frequency oscillatory ventilation uses very rapid, small breaths rather than the normal breathing pattern. The theory behind this approach is that the small tidal volumes might reduce lung injury while the rapid rate maintains gas exchange. However, large clinical trials have not demonstrated clear benefits from this strategy, and some studies even suggested potential harm. As a result, high frequency oscillatory ventilation remains primarily a research tool or last-resort option for the most severe cases of ARDS.
Airway pressure release ventilation is another alternative ventilator mode being studied. This technique maintains a high level of pressure in the airways most of the time, with brief releases of pressure that allow exhalation. The goal is to keep more of the lung open continuously while allowing some spontaneous breathing efforts by the patient. Research continues to evaluate whether this mode offers advantages over conventional ventilation strategies for ARDS patients.
Extracorporeal membrane oxygenation, commonly known as ECMO, represents the most advanced form of life support for severe ARDS. When mechanical ventilation cannot maintain adequate oxygen levels even with optimal settings, ECMO can temporarily take over some or all of the work of the lungs. During veno-venous ECMO (V-V ECMO), blood is removed from large veins, circulated through a machine that adds oxygen and removes carbon dioxide, then returned to the bloodstream. This allows healthcare providers to use very gentle ventilator settings that minimize further lung injury while the damaged lungs have time to heal.
ECMO is highly complex and carries significant risks including bleeding, blood clots, and infection. It requires specialized centers with trained teams available around the clock. Despite these challenges, studies suggest that ECMO may improve survival for carefully selected patients with the most severe ARDS. Current research focuses on identifying which patients benefit most from ECMO, the optimal timing for initiating this therapy, and the best techniques for managing patients while on ECMO support. Clinical trials examining ECMO for severe ARDS have been conducted at specialized centers in the United States, Europe, and other regions worldwide.
Researchers are exploring medications that might specifically target the underlying biological processes causing lung damage in ARDS. One area of investigation involves drugs that could reduce the excessive inflammatory response that characterizes ARDS. The challenge is that inflammation is part of the body’s normal defense mechanism, so completely blocking inflammation might increase infection risk. Scientists are working to identify therapies that can modulate rather than eliminate the inflammatory response, potentially reducing harm while preserving beneficial aspects of immunity.
Some clinical trials are examining whether identifying specific subtypes of ARDS could allow more targeted treatments. Researchers have identified patterns suggesting that ARDS is not a single uniform condition but rather a syndrome that can result from different biological pathways.
